tiprankstipranks
Trending News
More News >
Idexx Laboratories (IDXX)
NASDAQ:IDXX

Idexx Laboratories (IDXX) AI Stock Analysis

Compare
2,022 Followers

Top Page

ID

Idexx Laboratories

(NASDAQ:IDXX)

Rating:82Outperform
Price Target:
$609.00
▲(11.33%Upside)
Idexx Laboratories' strong financial performance and positive technical indicators are the primary drivers of its high score. The company's robust earnings call further supports a favorable outlook, despite a premium valuation and macroeconomic challenges.
Positive Factors
Financial Performance
First-quarter sales are in line with consensus while EPS are about 4% above Street expectations.
Market Position
Demand for IDXX's tests and consoles remain robust even in the face of an uneven macro.
Product Launch
The InVue Dx launch is an important growth accelerant for 2026 and beyond.
Negative Factors
Macroeconomic Challenges
Animal Health sentiment remains cautious due to challenged macroeconomic conditions and veterinary visit concerns.
Market Conditions
Veterinary office visits have been declining for the past 13 consecutive quarters in the US, impacting CAG growth.

Idexx Laboratories (IDXX) vs. SPDR S&P 500 ETF (SPY)

Idexx Laboratories Business Overview & Revenue Model

Company DescriptionIDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
How the Company Makes MoneyIDEXX Laboratories generates revenue through several key streams. The Companion Animal Group (CAG) is the largest segment, providing diagnostic instruments and consumables, reference laboratory services, and practice management software solutions to veterinary practices. Consumables and diagnostic services, which are recurring in nature, form a significant portion of the revenue within this segment. The Water segment contributes by supplying products and services that ensure water quality and safety, primarily through testing for microbiological contamination. The Livestock, Poultry, and Dairy (LPD) segment offers diagnostic tests and services to monitor animal health and improve productivity in farming operations. IDEXX also benefits from strategic partnerships with veterinary clinics and agricultural businesses, as well as continued investment in research and development to drive innovation and maintain a competitive edge in these industries.

Idexx Laboratories Key Performance Indicators (KPIs)

Any
Any
Revenue by Geography
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Chart InsightsIDEXX Laboratories is experiencing robust international revenue growth, driven by strong volume gains and price realization, as highlighted by an 8.5% increase in international CAG diagnostic recurring revenue. This contrasts with the U.S., where revenue growth is tempered by a decline in clinical visits. Despite these challenges, IDEXX's strategic focus on international markets and innovation, such as the launch of IDEXX Cancer Dx, positions it well for continued expansion. The company's updated outlook reflects confidence in overcoming macroeconomic pressures, with a sustained organic growth forecast of 6% to 9% for 2025.
Data provided by:Main Street Data

Idexx Laboratories Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q1-2025)
|
% Change Since: 26.43%|
Next Earnings Date:Aug 04, 2025
Earnings Call Sentiment Positive
The earnings call reflects a generally positive sentiment with strong revenue growth, successful product launches, and significant international expansion. However, there are challenges, including a decline in U.S. clinical visits and pressures from the macroeconomic and trade environment.
Q1-2025 Updates
Positive Updates
Solid Start to 2025
IDEXX achieved a solid start to 2025 with overall revenues increasing 5% organically, supported by a 4.5% organic growth in CAG Diagnostic recurring revenues.
Strong International Growth
International CAG diagnostic recurring revenue organic growth was 8.5%, reflecting benefits from net price realization and strong volume gains.
EPS and Profit Growth
EPS delivery was $2.96 per share, delivering 5% growth as reported and 7% growth on a comparable basis.
Expansion in Premium Instrument Install Base
IDEXX achieved a 9% expansion of the premium instrument install base and placed 1,544 instruments in the U.S., an increase of 12% year-over-year.
Launch of IDEXX Cancer Dx
IDEXX launched IDEXX Cancer Dx for early detection of canine lymphoma, with over 1,000 practices ordering the test within a month of launch.
Continued Innovation with IDEXX inVue Dx
Strong pre-order momentum and successful controlled launch of IDEXX inVue Dx, with over 900 placements through the end of April, transitioning to full launch.
Strong Software Ecosystem Performance
Veterinary software and diagnostic imaging revenues increased 9%, driven by reoccurring revenues and momentum in cloud-based software placements.
Resilient Pet Population
Estimated pet population sustained in 2024 at similar levels to the prior year, representing approximately 3% CAGR versus 2019 baseline.
Negative Updates
Decline in U.S. Clinical Visits
A 2.6% decline in U.S. clinical visits was noted, contributing to global same-store growth headwinds.
Decrease in CAG Instrument Revenues
CAG instrument revenues decreased 5% organically against high prior year placement levels.
Global Rapid Assay Revenue Decline
Global rapid assay revenues declined 2% organically in Q1 due to a shift in pancreatic lipase testing to catalyst instrument platforms.
Macroeconomic and Trade Environment Challenges
Ongoing challenges in the global trade environment and economic uncertainty have moderated growth.
Company Guidance
During the IDEXX Laboratories' first quarter 2025 earnings call, CFO Andrew Emerson reported a 5% organic revenue growth, driven by a 4.5% increase in CAG Diagnostic recurring revenues and a 9% growth in both veterinary software and diagnostic imaging. Despite a 2.6% decline in U.S. clinical visits, IDEXX achieved an EPS of $2.96, reflecting a 5% increase as reported and a 7% growth on a comparable basis. The company placed 4,163 CAG premium instruments, although this represented a 13% decline from the previous year, with U.S. placements up by 12%. IDEXX sustained a strong customer base, with a 9% rise in the global premium instrument installed base, and maintained a 7% organic growth in water and 4% in livestock, poultry, and dairy revenues. The company updated its 2025 outlook to account for foreign exchange benefits and concluded litigation expenses while holding its full-year organic growth forecast at 6% to 9%.

Idexx Laboratories Financial Statement Overview

Summary
Idexx Laboratories demonstrates strong financial health with robust profitability and cash flow metrics. The company shows consistent revenue and profit growth, efficient operations, and strong cash generation. While the balance sheet is stable, attention to debt management could enhance financial flexibility.
Income Statement
90
Very Positive
Idexx Laboratories demonstrates strong profitability with a TTM gross profit margin of 61.3% and a net profit margin of 22.8%. The company has shown consistent revenue growth, with a TTM revenue increase of 1.2% compared to the previous year. EBIT and EBITDA margins are robust at 29.2% and 32.0% respectively, indicating efficient operations. The company is performing well in terms of profitability, although the revenue growth rate has slowed compared to historical figures.
Balance Sheet
75
Positive
The company's balance sheet is relatively stable with a debt-to-equity ratio of 0.34, reflecting moderate leverage. The return on equity (ROE) is strong at 61.8%, demonstrating effective use of shareholder funds. However, the equity ratio of 45.1% suggests a balanced capital structure with room for improvement in asset financing. Overall, the balance sheet is solid, though attention to debt management is advised.
Cash Flow
85
Very Positive
Idexx Laboratories maintains healthy cash flow with a free cash flow growth rate of 5.0% over the last year. The operating cash flow to net income ratio is 1.08, indicating strong cash generation relative to profits. The free cash flow to net income ratio of 0.94 further underscores the company’s efficient cash conversion. While the cash flow metrics are robust, a slight decline in operating cash flow growth compared to past trends is noted.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.93B3.90B3.66B3.37B3.22B2.71B
Gross Profit2.41B2.38B2.19B2.00B1.89B1.57B
EBITDA1.29B1.28B1.22B1.01B1.04B793.81M
Net Income894.97M887.87M845.04M679.09M744.85M581.78M
Balance Sheet
Total Assets3.21B3.29B3.26B2.75B2.44B2.29B
Cash, Cash Equivalents and Short-Term Investments163.97M288.27M453.93M112.55M144.45M383.93M
Total Debt1.06B986.95M1.07B1.35B923.70M908.48M
Total Liabilities1.77B1.70B1.78B2.14B1.75B1.66B
Stockholders Equity1.45B1.60B1.48B608.74M689.99M632.09M
Cash Flow
Free Cash Flow837.70M798.08M772.88M394.15M636.00M540.44M
Operating Cash Flow968.38M929.00M906.51M542.98M755.55M648.06M
Investing Cash Flow-129.73M-207.06M-125.25M-195.35M-292.97M-109.38M
Financing Cash Flow-1.06B-878.07M-442.00M-370.94M-697.41M-248.42M

Idexx Laboratories Technical Analysis

Technical Analysis Sentiment
Positive
Last Price547.01
Price Trends
50DMA
502.90
Positive
100DMA
464.44
Positive
200DMA
454.78
Positive
Market Momentum
MACD
9.83
Positive
RSI
69.93
Neutral
STOCH
90.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXX, the sentiment is Positive. The current price of 547.01 is above the 20-day moving average (MA) of 527.49, above the 50-day MA of 502.90, and above the 200-day MA of 454.78, indicating a bullish trend. The MACD of 9.83 indicates Positive momentum. The RSI at 69.93 is Neutral, neither overbought nor oversold. The STOCH value of 90.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDXX.

Idexx Laboratories Risk Analysis

Idexx Laboratories disclosed 24 risk factors in its most recent earnings report. Idexx Laboratories reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Idexx Laboratories Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$43.65B50.1559.33%5.56%4.66%
AA
79
Outperform
$34.22B29.7118.88%0.82%0.56%-4.08%
DGDGX
79
Outperform
$19.71B22.3213.35%1.81%9.38%6.43%
WAWAT
73
Outperform
$20.94B31.9140.82%2.57%8.31%
68
Neutral
$11.89B39.893.82%0.28%1.62%78.53%
MTMTD
64
Neutral
$25.06B30.07-680.23%1.18%12.34%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IDXX
Idexx Laboratories
547.01
61.01
12.55%
A
Agilent
121.38
-4.02
-3.21%
MTD
Mettler-Toledo
1,209.08
-137.00
-10.18%
RVTY
Revvity
101.31
-1.99
-1.93%
DGX
Quest Diagnostics
176.92
39.26
28.52%
WAT
Waters
350.22
64.01
22.36%

Idexx Laboratories Corporate Events

Shareholder MeetingsBusiness Operations and StrategyRegulatory Filings and Compliance
IDEXX Laboratories Updates Corporate Governance Structure
Neutral
May 9, 2025

On May 7, 2025, IDEXX Laboratories, Inc. made significant amendments to its corporate governance structure. The company filed a Certificate of Elimination to remove the designation of its Series A Junior Participating Preferred Stock and amended its Certificate of Incorporation to eliminate supermajority voting provisions and allow officer exculpation as per Delaware law. Additionally, the company updated its By-Laws to reflect these changes and establish Delaware courts as the exclusive forum for certain legal actions. These amendments, approved during the 2025 Annual Meeting, aim to streamline corporate governance and align with current legal standards, potentially impacting shareholder engagement and corporate decision-making processes.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 05, 2025